Vinci Pharmaceuticals Inc. schließt Serie-A-Finanzierung über mehr als 8 Millionen US-Dollar zur Weiterentwicklung der EPIPLANT™-Wirkstofffreisetzungsplattform ab

EPIPLANT™Positive

AI Analysis

Summary

Vinci Pharmaceuticals closed a Series A financing round of over $8 million to advance its EPIPLANT drug delivery platform. Combined with previous seed funding of $8.5 million, the company has raised more than $16.5 million total.

Importance:5/10

Sentiment:

0.70

Series A FinancingDrug Delivery PlatformCapital Raise

Read the original article

Published by PR Newswire Biotech on October 8, 2026 6:41 PM

Read Original